ADBRY® (tralokinumab-ldrm) & Pregnancy Study

MotherToBaby is currently enrolling pregnant people in a study examining the use of ADBRY® (tralokinumab-ldrm) to treat moderate-to-severe eczema (atopic dermatitis) when taken during pregnancy. The study is conducted through phone interviews—no changes to your normal routine or travel required. If you’ve taken ADBRY® and are pregnant, you may qualify for this important study.‎ 

Our study includes:

• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your and your baby’s medical records from your healthcare providers.
• An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor
• A neurodevelopmental assessment that can also provide insight into the child’s development at approximately 4 months and 12 months of age

“Help us improve the ability for pregnant people and their healthcare providers to make more informed treatment decisions by joining our ADBRY® & Pregnancy Study.”

— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Make an impact on maternal health by enrolling into our pregnancy study!